Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published Date September 2008 Volume 2008:4(4) Pages 821—826

DOI http://dx.doi.org/10.2147/TCRM.S3075

Published 1 September 2008

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Fabrication of genistein-loaded biodegradable TPGS-b-PCL nanoparticles for improved therapeutic effects in cervical cancer cells

Zhang H, Liu G, Zeng X, Wu Y, Yang C, Mei L, Wang Z, Huang L

International Journal of Nanomedicine 2015, 10:2461-2473

Published Date: 27 March 2015

Staphylococcus aureus eye infections in two Indian hospitals: emergence of ST772 as a major clone

Nadig S, Velusamy N, Lalitha P, Kar S, Sharma S, Arakere G

Clinical Ophthalmology 2012, 6:165-173

Published Date: 24 January 2012

Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering

Chen YP, Zheng XW, Chen G, He C, Zhu WF, Feng SY, Xi G, Chen R, Lan FH, Zeng HS

International Journal of Nanomedicine 2012, 7:73-82

Published Date: 30 December 2011

Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study

Schlachter EK, Widmer HR, Bregy A, Lönnfors-Weitzel T, Vajtai I, Corazza N, Bernau VJP, Weitzel T, Mordasini P, Slotboom J, Herrmann G, Bogni S, Hofmann H, Frenz M, Reinert M

International Journal of Nanomedicine 2011, 6:1793-1800

Published Date: 26 August 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation

Banny S Wong, Noriaki Manabe, Michael Camilleri

Clinical and Experimental Gastroenterology 2010, 3:49-56

Published Date: 24 May 2010

Postoperative delirium in the elderly: diagnosis and management

Thomas N Robinson, Ben Eiseman

Clinical Interventions in Aging 2008, 3:351-355

Published Date: 30 June 2008